Published Date: 04/11/2011
Category: Drug Delivery & Devices
Depomed, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.Features:Detailed information on Depomed, Inc. required for business and competitor intelligence needsA study of the major internal and external factors affecting Depomed, Inc. in the form of a SWOT analysisAn in-depth view of the business model of Depomed, Inc. including a breakdown and examination of key business segmentsIntelligence on Depomed, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisorsNews about Depomed, Inc., such as business expansion, restructuring, and contract winsLarge number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Purchase: Gain understanding of Depomed, Inc. and the factors that influence its strategies Track strategic initiatives of the company and latest corporate news and actions Assess Depomed, Inc. as a prospective partner, vendor or supplier Support sales activities by understanding your customers' businesses better Stay up to date on Depomed, Inc.’s business structure, strategy and prospects
Depomed, Inc
Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. The company primarily operates in the US. Depomed is headquartered in Menlo Park, California and employed 70 people as of December 31, 2010. The company recorded revenues of $80.8 million during the financial year (FY) ended December 2010, an increase of 39.9% over FY2009. The operating profit of the company was $3.6 million during FY2010, as compared to an operating loss of $22.1 million in FY2009. The net profit was $3.9 million in FY2010, as compared to a net loss of $22 million in FY2009.